Report cover image

Global DTaP and Tdap Vaccines Market Outlook and Growth Opportunities 2025

Publisher APO Research, Inc.
Published Oct 20, 2025
Length 192 Pages
SKU # APRC20556131

Description

Summary

According to APO Research, the global DTaP and Tdap Vaccines market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for DTaP and Tdap Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Asia-Pacific market for DTaP and Tdap Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the DTaP and Tdap Vaccines market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Europe market for DTaP and Tdap Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the DTaP and Tdap Vaccines market include Johnson & Johnson, Novartis AG, Lanzhou Institute of Biological Products Co., Ltd, Pfizer Inc, GlaxoSmithKline, AstraZeneca, Seqirus, Sanofi Pasteur and Protein Sciences Corporation, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for DTaP and Tdap Vaccines, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of DTaP and Tdap Vaccines, also provides the sales of main regions and countries. Of the upcoming market potential for DTaP and Tdap Vaccines, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the DTaP and Tdap Vaccines sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global DTaP and Tdap Vaccines market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for DTaP and Tdap Vaccines sales, projected growth trends, production technology, application and end-user industry.

DTaP and Tdap Vaccines Segment by Company

Johnson & Johnson
Novartis AG
Lanzhou Institute of Biological Products Co., Ltd
Pfizer Inc
GlaxoSmithKline
AstraZeneca
Seqirus
Sanofi Pasteur
Protein Sciences Corporation
Merck Sharp & Dohme Corp
Emergent BioSolutions Inc
Astellas Pharma US, Inc
DTaP and Tdap Vaccines Segment by Type

Tdap
DTaP
Td
DTaP and Tdap Vaccines Segment by Application

Adult
Pediatric
DTaP and Tdap Vaccines Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global DTaP and Tdap Vaccines status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions DTaP and Tdap Vaccines market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify DTaP and Tdap Vaccines significant trends, drivers, influence factors in global and regions.
6. To analyze DTaP and Tdap Vaccines competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global DTaP and Tdap Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of DTaP and Tdap Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of DTaP and Tdap Vaccines.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the DTaP and Tdap Vaccines market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global DTaP and Tdap Vaccines industry.
Chapter 3: Detailed analysis of DTaP and Tdap Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of DTaP and Tdap Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of DTaP and Tdap Vaccines in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

192 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global DTaP and Tdap Vaccines Sales Value (2020-2031)
1.2.2 Global DTaP and Tdap Vaccines Sales Volume (2020-2031)
1.2.3 Global DTaP and Tdap Vaccines Sales Average Price (2020-2031)
1.3 Assumptions and Limitations
1.4 Study Goals and Objectives
2 DTaP and Tdap Vaccines Market Dynamics
2.1 DTaP and Tdap Vaccines Industry Trends
2.2 DTaP and Tdap Vaccines Industry Drivers
2.3 DTaP and Tdap Vaccines Industry Opportunities and Challenges
2.4 DTaP and Tdap Vaccines Industry Restraints
3 DTaP and Tdap Vaccines Market by Company
3.1 Global DTaP and Tdap Vaccines Company Revenue Ranking in 2024
3.2 Global DTaP and Tdap Vaccines Revenue by Company (2020-2025)
3.3 Global DTaP and Tdap Vaccines Sales Volume by Company (2020-2025)
3.4 Global DTaP and Tdap Vaccines Average Price by Company (2020-2025)
3.5 Global DTaP and Tdap Vaccines Company Ranking (2023-2025)
3.6 Global DTaP and Tdap Vaccines Company Manufacturing Base and Headquarters
3.7 Global DTaP and Tdap Vaccines Company Product Type and Application
3.8 Global DTaP and Tdap Vaccines Company Establishment Date
3.9 Market Competitive Analysis
3.9.1 Global DTaP and Tdap Vaccines Market Concentration Ratio (CR5 and HHI)
3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.9.3 2024 DTaP and Tdap Vaccines Tier 1, Tier 2, and Tier 3 Companies
3.10 Mergers and Acquisitions Expansion
4 DTaP and Tdap Vaccines Market by Type
4.1 DTaP and Tdap Vaccines Type Introduction
4.1.1 Tdap
4.1.2 DTaP
4.1.3 Td
4.2 Global DTaP and Tdap Vaccines Sales Volume by Type
4.2.1 Global DTaP and Tdap Vaccines Sales Volume by Type (2020 VS 2024 VS 2031)
4.2.2 Global DTaP and Tdap Vaccines Sales Volume by Type (2020-2031)
4.2.3 Global DTaP and Tdap Vaccines Sales Volume Share by Type (2020-2031)
4.3 Global DTaP and Tdap Vaccines Sales Value by Type
4.3.1 Global DTaP and Tdap Vaccines Sales Value by Type (2020 VS 2024 VS 2031)
4.3.2 Global DTaP and Tdap Vaccines Sales Value by Type (2020-2031)
4.3.3 Global DTaP and Tdap Vaccines Sales Value Share by Type (2020-2031)
5 DTaP and Tdap Vaccines Market by Application
5.1 DTaP and Tdap Vaccines Application Introduction
5.1.1 Adult
5.1.2 Pediatric
5.2 Global DTaP and Tdap Vaccines Sales Volume by Application
5.2.1 Global DTaP and Tdap Vaccines Sales Volume by Application (2020 VS 2024 VS 2031)
5.2.2 Global DTaP and Tdap Vaccines Sales Volume by Application (2020-2031)
5.2.3 Global DTaP and Tdap Vaccines Sales Volume Share by Application (2020-2031)
5.3 Global DTaP and Tdap Vaccines Sales Value by Application
5.3.1 Global DTaP and Tdap Vaccines Sales Value by Application (2020 VS 2024 VS 2031)
5.3.2 Global DTaP and Tdap Vaccines Sales Value by Application (2020-2031)
5.3.3 Global DTaP and Tdap Vaccines Sales Value Share by Application (2020-2031)
6 DTaP and Tdap Vaccines Regional Sales and Value Analysis
6.1 Global DTaP and Tdap Vaccines Sales by Region: 2020 VS 2024 VS 2031
6.2 Global DTaP and Tdap Vaccines Sales by Region (2020-2031)
6.2.1 Global DTaP and Tdap Vaccines Sales by Region: 2020-2025
6.2.2 Global DTaP and Tdap Vaccines Sales by Region (2026-2031)
6.3 Global DTaP and Tdap Vaccines Sales Value by Region: 2020 VS 2024 VS 2031
6.4 Global DTaP and Tdap Vaccines Sales Value by Region (2020-2031)
6.4.1 Global DTaP and Tdap Vaccines Sales Value by Region: 2020-2025
6.4.2 Global DTaP and Tdap Vaccines Sales Value by Region (2026-2031)
6.5 Global DTaP and Tdap Vaccines Market Price Analysis by Region (2020-2025)
6.6 North America
6.6.1 North America DTaP and Tdap Vaccines Sales Value (2020-2031)
6.6.2 North America DTaP and Tdap Vaccines Sales Value Share by Country, 2024 VS 2031
6.7 Europe
6.7.1 Europe DTaP and Tdap Vaccines Sales Value (2020-2031)
6.7.2 Europe DTaP and Tdap Vaccines Sales Value Share by Country, 2024 VS 2031
6.8 Asia-Pacific
6.8.1 Asia-Pacific DTaP and Tdap Vaccines Sales Value (2020-2031)
6.8.2 Asia-Pacific DTaP and Tdap Vaccines Sales Value Share by Country, 2024 VS 2031
6.9 South America
6.9.1 South America DTaP and Tdap Vaccines Sales Value (2020-2031)
6.9.2 South America DTaP and Tdap Vaccines Sales Value Share by Country, 2024 VS 2031
6.10 Middle East & Africa
6.10.1 Middle East & Africa DTaP and Tdap Vaccines Sales Value (2020-2031)
6.10.2 Middle East & Africa DTaP and Tdap Vaccines Sales Value Share by Country, 2024 VS 2031
7 DTaP and Tdap Vaccines Country-level Sales and Value Analysis
7.1 Global DTaP and Tdap Vaccines Sales by Country: 2020 VS 2024 VS 2031
7.2 Global DTaP and Tdap Vaccines Sales Value by Country: 2020 VS 2024 VS 2031
7.3 Global DTaP and Tdap Vaccines Sales by Country (2020-2031)
7.3.1 Global DTaP and Tdap Vaccines Sales by Country (2020-2025)
7.3.2 Global DTaP and Tdap Vaccines Sales by Country (2026-2031)
7.4 Global DTaP and Tdap Vaccines Sales Value by Country (2020-2031)
7.4.1 Global DTaP and Tdap Vaccines Sales Value by Country (2020-2025)
7.4.2 Global DTaP and Tdap Vaccines Sales Value by Country (2026-2031)
7.5 USA
7.5.1 USA DTaP and Tdap Vaccines Sales Value Growth Rate (2020-2031)
7.5.2 USA DTaP and Tdap Vaccines Sales Value Share by Type, 2024 VS 2031
7.5.3 USA DTaP and Tdap Vaccines Sales Value Share by Application, 2024 VS 2031
7.6 Canada
7.6.1 Canada DTaP and Tdap Vaccines Sales Value Growth Rate (2020-2031)
7.6.2 Canada DTaP and Tdap Vaccines Sales Value Share by Type, 2024 VS 2031
7.6.3 Canada DTaP and Tdap Vaccines Sales Value Share by Application, 2024 VS 2031
7.7 Mexico
7.6.1 Mexico DTaP and Tdap Vaccines Sales Value Growth Rate (2020-2031)
7.6.2 Mexico DTaP and Tdap Vaccines Sales Value Share by Type, 2024 VS 2031
7.6.3 Mexico DTaP and Tdap Vaccines Sales Value Share by Application, 2024 VS 2031
7.8 Germany
7.8.1 Germany DTaP and Tdap Vaccines Sales Value Growth Rate (2020-2031)
7.8.2 Germany DTaP and Tdap Vaccines Sales Value Share by Type, 2024 VS 2031
7.8.3 Germany DTaP and Tdap Vaccines Sales Value Share by Application, 2024 VS 2031
7.9 France
7.9.1 France DTaP and Tdap Vaccines Sales Value Growth Rate (2020-2031)
7.9.2 France DTaP and Tdap Vaccines Sales Value Share by Type, 2024 VS 2031
7.9.3 France DTaP and Tdap Vaccines Sales Value Share by Application, 2024 VS 2031
7.10 U.K.
7.10.1 U.K. DTaP and Tdap Vaccines Sales Value Growth Rate (2020-2031)
7.10.2 U.K. DTaP and Tdap Vaccines Sales Value Share by Type, 2024 VS 2031
7.10.3 U.K. DTaP and Tdap Vaccines Sales Value Share by Application, 2024 VS 2031
7.11 Italy
7.11.1 Italy DTaP and Tdap Vaccines Sales Value Growth Rate (2020-2031)
7.11.2 Italy DTaP and Tdap Vaccines Sales Value Share by Type, 2024 VS 2031
7.11.3 Italy DTaP and Tdap Vaccines Sales Value Share by Application, 2024 VS 2031
7.12 Spain
7.12.1 Spain DTaP and Tdap Vaccines Sales Value Growth Rate (2020-2031)
7.12.2 Spain DTaP and Tdap Vaccines Sales Value Share by Type, 2024 VS 2031
7.12.3 Spain DTaP and Tdap Vaccines Sales Value Share by Application, 2024 VS 2031
7.13 Russia
7.13.1 Russia DTaP and Tdap Vaccines Sales Value Growth Rate (2020-2031)
7.13.2 Russia DTaP and Tdap Vaccines Sales Value Share by Type, 2024 VS 2031
7.13.3 Russia DTaP and Tdap Vaccines Sales Value Share by Application, 2024 VS 2031
7.14 Netherlands
7.14.1 Netherlands DTaP and Tdap Vaccines Sales Value Growth Rate (2020-2031)
7.14.2 Netherlands DTaP and Tdap Vaccines Sales Value Share by Type, 2024 VS 2031
7.14.3 Netherlands DTaP and Tdap Vaccines Sales Value Share by Application, 2024 VS 2031
7.15 Nordic Countries
7.15.1 Nordic Countries DTaP and Tdap Vaccines Sales Value Growth Rate (2020-2031)
7.15.2 Nordic Countries DTaP and Tdap Vaccines Sales Value Share by Type, 2024 VS 2031
7.15.3 Nordic Countries DTaP and Tdap Vaccines Sales Value Share by Application, 2024 VS 2031
7.16 China
7.16.1 China DTaP and Tdap Vaccines Sales Value Growth Rate (2020-2031)
7.16.2 China DTaP and Tdap Vaccines Sales Value Share by Type, 2024 VS 2031
7.16.3 China DTaP and Tdap Vaccines Sales Value Share by Application, 2024 VS 2031
7.17 Japan
7.17.1 Japan DTaP and Tdap Vaccines Sales Value Growth Rate (2020-2031)
7.17.2 Japan DTaP and Tdap Vaccines Sales Value Share by Type, 2024 VS 2031
7.17.3 Japan DTaP and Tdap Vaccines Sales Value Share by Application, 2024 VS 2031
7.18 South Korea
7.18.1 South Korea DTaP and Tdap Vaccines Sales Value Growth Rate (2020-2031)
7.18.2 South Korea DTaP and Tdap Vaccines Sales Value Share by Type, 2024 VS 2031
7.18.3 South Korea DTaP and Tdap Vaccines Sales Value Share by Application, 2024 VS 2031
7.19 India
7.19.1 India DTaP and Tdap Vaccines Sales Value Growth Rate (2020-2031)
7.19.2 India DTaP and Tdap Vaccines Sales Value Share by Type, 2024 VS 2031
7.19.3 India DTaP and Tdap Vaccines Sales Value Share by Application, 2024 VS 2031
7.20 Australia
7.20.1 Australia DTaP and Tdap Vaccines Sales Value Growth Rate (2020-2031)
7.20.2 Australia DTaP and Tdap Vaccines Sales Value Share by Type, 2024 VS 2031
7.20.3 Australia DTaP and Tdap Vaccines Sales Value Share by Application, 2024 VS 2031
7.21 Southeast Asia
7.21.1 Southeast Asia DTaP and Tdap Vaccines Sales Value Growth Rate (2020-2031)
7.21.2 Southeast Asia DTaP and Tdap Vaccines Sales Value Share by Type, 2024 VS 2031
7.21.3 Southeast Asia DTaP and Tdap Vaccines Sales Value Share by Application, 2024 VS 2031
7.22 Brazil
7.22.1 Brazil DTaP and Tdap Vaccines Sales Value Growth Rate (2020-2031)
7.22.2 Brazil DTaP and Tdap Vaccines Sales Value Share by Type, 2024 VS 2031
7.22.3 Brazil DTaP and Tdap Vaccines Sales Value Share by Application, 2024 VS 2031
7.23 Argentina
7.23.1 Argentina DTaP and Tdap Vaccines Sales Value Growth Rate (2020-2031)
7.23.2 Argentina DTaP and Tdap Vaccines Sales Value Share by Type, 2024 VS 2031
7.23.3 Argentina DTaP and Tdap Vaccines Sales Value Share by Application, 2024 VS 2031
7.24 Chile
7.24.1 Chile DTaP and Tdap Vaccines Sales Value Growth Rate (2020-2031)
7.24.2 Chile DTaP and Tdap Vaccines Sales Value Share by Type, 2024 VS 2031
7.24.3 Chile DTaP and Tdap Vaccines Sales Value Share by Application, 2024 VS 2031
7.25 Colombia
7.25.1 Colombia DTaP and Tdap Vaccines Sales Value Growth Rate (2020-2031)
7.25.2 Colombia DTaP and Tdap Vaccines Sales Value Share by Type, 2024 VS 2031
7.25.3 Colombia DTaP and Tdap Vaccines Sales Value Share by Application, 2024 VS 2031
7.26 Peru
7.26.1 Peru DTaP and Tdap Vaccines Sales Value Growth Rate (2020-2031)
7.26.2 Peru DTaP and Tdap Vaccines Sales Value Share by Type, 2024 VS 2031
7.26.3 Peru DTaP and Tdap Vaccines Sales Value Share by Application, 2024 VS 2031
7.27 Saudi Arabia
7.27.1 Saudi Arabia DTaP and Tdap Vaccines Sales Value Growth Rate (2020-2031)
7.27.2 Saudi Arabia DTaP and Tdap Vaccines Sales Value Share by Type, 2024 VS 2031
7.27.3 Saudi Arabia DTaP and Tdap Vaccines Sales Value Share by Application, 2024 VS 2031
7.28 Israel
7.28.1 Israel DTaP and Tdap Vaccines Sales Value Growth Rate (2020-2031)
7.28.2 Israel DTaP and Tdap Vaccines Sales Value Share by Type, 2024 VS 2031
7.28.3 Israel DTaP and Tdap Vaccines Sales Value Share by Application, 2024 VS 2031
7.29 UAE
7.29.1 UAE DTaP and Tdap Vaccines Sales Value Growth Rate (2020-2031)
7.29.2 UAE DTaP and Tdap Vaccines Sales Value Share by Type, 2024 VS 2031
7.29.3 UAE DTaP and Tdap Vaccines Sales Value Share by Application, 2024 VS 2031
7.30 Turkey
7.30.1 Turkey DTaP and Tdap Vaccines Sales Value Growth Rate (2020-2031)
7.30.2 Turkey DTaP and Tdap Vaccines Sales Value Share by Type, 2024 VS 2031
7.30.3 Turkey DTaP and Tdap Vaccines Sales Value Share by Application, 2024 VS 2031
7.31 Iran
7.31.1 Iran DTaP and Tdap Vaccines Sales Value Growth Rate (2020-2031)
7.31.2 Iran DTaP and Tdap Vaccines Sales Value Share by Type, 2024 VS 2031
7.31.3 Iran DTaP and Tdap Vaccines Sales Value Share by Application, 2024 VS 2031
7.32 Egypt
7.32.1 Egypt DTaP and Tdap Vaccines Sales Value Growth Rate (2020-2031)
7.32.2 Egypt DTaP and Tdap Vaccines Sales Value Share by Type, 2024 VS 2031
7.32.3 Egypt DTaP and Tdap Vaccines Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 Johnson & Johnson
8.1.1 Johnson & Johnson Comapny Information
8.1.2 Johnson & Johnson Business Overview
8.1.3 Johnson & Johnson DTaP and Tdap Vaccines Sales, Value and Gross Margin (2020-2025)
8.1.4 Johnson & Johnson DTaP and Tdap Vaccines Product Portfolio
8.1.5 Johnson & Johnson Recent Developments
8.2 Novartis AG
8.2.1 Novartis AG Comapny Information
8.2.2 Novartis AG Business Overview
8.2.3 Novartis AG DTaP and Tdap Vaccines Sales, Value and Gross Margin (2020-2025)
8.2.4 Novartis AG DTaP and Tdap Vaccines Product Portfolio
8.2.5 Novartis AG Recent Developments
8.3 Lanzhou Institute of Biological Products Co., Ltd
8.3.1 Lanzhou Institute of Biological Products Co., Ltd Comapny Information
8.3.2 Lanzhou Institute of Biological Products Co., Ltd Business Overview
8.3.3 Lanzhou Institute of Biological Products Co., Ltd DTaP and Tdap Vaccines Sales, Value and Gross Margin (2020-2025)
8.3.4 Lanzhou Institute of Biological Products Co., Ltd DTaP and Tdap Vaccines Product Portfolio
8.3.5 Lanzhou Institute of Biological Products Co., Ltd Recent Developments
8.4 Pfizer Inc
8.4.1 Pfizer Inc Comapny Information
8.4.2 Pfizer Inc Business Overview
8.4.3 Pfizer Inc DTaP and Tdap Vaccines Sales, Value and Gross Margin (2020-2025)
8.4.4 Pfizer Inc DTaP and Tdap Vaccines Product Portfolio
8.4.5 Pfizer Inc Recent Developments
8.5 GlaxoSmithKline
8.5.1 GlaxoSmithKline Comapny Information
8.5.2 GlaxoSmithKline Business Overview
8.5.3 GlaxoSmithKline DTaP and Tdap Vaccines Sales, Value and Gross Margin (2020-2025)
8.5.4 GlaxoSmithKline DTaP and Tdap Vaccines Product Portfolio
8.5.5 GlaxoSmithKline Recent Developments
8.6 AstraZeneca
8.6.1 AstraZeneca Comapny Information
8.6.2 AstraZeneca Business Overview
8.6.3 AstraZeneca DTaP and Tdap Vaccines Sales, Value and Gross Margin (2020-2025)
8.6.4 AstraZeneca DTaP and Tdap Vaccines Product Portfolio
8.6.5 AstraZeneca Recent Developments
8.7 Seqirus
8.7.1 Seqirus Comapny Information
8.7.2 Seqirus Business Overview
8.7.3 Seqirus DTaP and Tdap Vaccines Sales, Value and Gross Margin (2020-2025)
8.7.4 Seqirus DTaP and Tdap Vaccines Product Portfolio
8.7.5 Seqirus Recent Developments
8.8 Sanofi Pasteur
8.8.1 Sanofi Pasteur Comapny Information
8.8.2 Sanofi Pasteur Business Overview
8.8.3 Sanofi Pasteur DTaP and Tdap Vaccines Sales, Value and Gross Margin (2020-2025)
8.8.4 Sanofi Pasteur DTaP and Tdap Vaccines Product Portfolio
8.8.5 Sanofi Pasteur Recent Developments
8.9 Protein Sciences Corporation
8.9.1 Protein Sciences Corporation Comapny Information
8.9.2 Protein Sciences Corporation Business Overview
8.9.3 Protein Sciences Corporation DTaP and Tdap Vaccines Sales, Value and Gross Margin (2020-2025)
8.9.4 Protein Sciences Corporation DTaP and Tdap Vaccines Product Portfolio
8.9.5 Protein Sciences Corporation Recent Developments
8.10 Merck Sharp & Dohme Corp
8.10.1 Merck Sharp & Dohme Corp Comapny Information
8.10.2 Merck Sharp & Dohme Corp Business Overview
8.10.3 Merck Sharp & Dohme Corp DTaP and Tdap Vaccines Sales, Value and Gross Margin (2020-2025)
8.10.4 Merck Sharp & Dohme Corp DTaP and Tdap Vaccines Product Portfolio
8.10.5 Merck Sharp & Dohme Corp Recent Developments
8.11 Emergent BioSolutions Inc
8.11.1 Emergent BioSolutions Inc Comapny Information
8.11.2 Emergent BioSolutions Inc Business Overview
8.11.3 Emergent BioSolutions Inc DTaP and Tdap Vaccines Sales, Value and Gross Margin (2020-2025)
8.11.4 Emergent BioSolutions Inc DTaP and Tdap Vaccines Product Portfolio
8.11.5 Emergent BioSolutions Inc Recent Developments
8.12 Astellas Pharma US, Inc
8.12.1 Astellas Pharma US, Inc Comapny Information
8.12.2 Astellas Pharma US, Inc Business Overview
8.12.3 Astellas Pharma US, Inc DTaP and Tdap Vaccines Sales, Value and Gross Margin (2020-2025)
8.12.4 Astellas Pharma US, Inc DTaP and Tdap Vaccines Product Portfolio
8.12.5 Astellas Pharma US, Inc Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 DTaP and Tdap Vaccines Value Chain Analysis
9.1.1 DTaP and Tdap Vaccines Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 DTaP and Tdap Vaccines Sales Mode & Process
9.2 DTaP and Tdap Vaccines Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 DTaP and Tdap Vaccines Distributors
9.2.3 DTaP and Tdap Vaccines Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.